25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients

United European Gastroenterology Journal

Volumn 5, Issue 1, 2017, Pages 69-75

  Belle, Arthur ^a   Gizard, Emmanuel ^a   Conroy, Guillaume ^a   Lopez, Anthony ^a   Bouvier Alias, Magali ^b,c   Rouanet, Stéphanie ^d   Peyrin Biroulet, Laurent ^a   Pawlotsky, Jean Michel ^b,c   Bronowicki, Jean Pierre ^a  

^a CHU NANCY BRABOIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSERM U955   (France)

^d Roche   (France)

Author keywords

fibrosis; hepatitis C; viral response; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH IMPACT ASSESSMENT; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIMIT OF DETECTION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE;

EID: 85011607412     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640616640157     Document Type: Article

References (45)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107–115.
2. European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392–420.
3. Pawlotsky JM. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176–1192.
4. Lawitz E, Mangia A, Wyles D. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–1887.
5. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004; 26: 21–28.
6. Hewison M. Vitamin D and the immune system: New perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39: 365–379.
7. Ladero JM, Torrejón MJ, Sánchez-Pobre P. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol 2013; 12: 199–204.
8. Lange CM, Bojunga J, Ramos-Lopez E. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887–893.
9. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624–2628.
10. Petta S, Cammà C, Scazzone C. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158–1167.
11. Bitetto D, Fabris C, Fornasiere E. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 43–50.
12. Bitetto D, Fattovich G, Fabris C. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118–1126.
13. Falleti E, Bitetto D, Fabris C. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012; 56: 1641–1650.
14. Kitson MT, Dore GJ, Button G. Vitamin D status is associated with complete EVR but not SVR in chronic hepatitis C genotype 1 infection: Analysis of the Australasian Chariot study cohort. J Hepatol 2012; 56(Suppl 2): S443–S444.
15. Kitson MT, Dore GJ, George J. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013; 58: 467–472.
16. Abramovitch S, Dahan-Bachar L, Sharvit E. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011; 60: 1728–1737.
17. Cammà C, Scazzone C, Tripodo C. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158–1167.
18. Bronowicki JP, Ouzan D, Asselah T. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 1040–1048.
19. Gal-Tanamy M, Bachmetov L, Ravid A. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570–1579.
20. Shen L. Vitamin D controls T cell activation: Implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C. Hepatology 2010; 52: 1864–1864.
21. Grammatikos G, Lange C, Susser S. Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One 2014; 9: e87974–e87974.
22. Petta S, Ferraro D, Cammà C. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther 2012; 17: 823–831.
23. Abu-Mouch S, Fireman Z, Jarchovsky J. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184–5190.
24. García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis. Hepatology 2014; 60: 1541–1550.
25. Kitson MT, Sarrazin C, Toniutto P. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. J Hepatol 2014; 61: 1247–1252.
26. Petta S, Grimaudo S, Marco VD. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepat 2013; 20: 486–493.
27. Terrier B, Carrat F, Geri G. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756–761.
28. Ho AS, Cheng CC, Lee SC. Novel biomarkers predict liver fibrosis in hepatitis C patients: Alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010; 17: 58–58.
29. Baur K, Mertens JC, Schmitt J. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 635–643.
30. Kondo Y, Kato T, Kimura O. 1(OH) Vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients – case controlled trial. PLoS One 2013; 8: e63672–e63672.
31. Jacobson IM, McHutchison JG, Dusheiko G. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416.
32. Zeuzem S, Andreone P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–2428.
33. Kwo PY, Lawitz EJ, McCone J. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–716.
34. Poordad F, McCone J, Bacon BR. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
35. Esmat G, El Raziky M, Elsharkawy A. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res 2015; 35: 49–54.
36. Agence française de sécurité sanitaire des produits de santé. Recommandations à destination des biologistes concernant la spécificité des dosages de vitamine D. 2009, http://www.ansm.sante.fr/var/ansm_site/storage/original/application/b8d261e1e6faae42c5423a93bc104224.pdf
37. Schiefke I, Fach A, Wiedmann M. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843–1847.
38. Arase Y, Suzuki F, Suzuki Y. Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 2010; 82: 390–395.
39. Corazza GR, Trevisani F, Di Stefano M. Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 2000; 45: 1392–1399.
40. Solís-Herruzo JA, Castellano G, Fernández I. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 812–817.
41. Moreira RO, Balduíno A, Martins HS. Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2004; 75: 160–168.
42. Trombetti A, Giostra E, Mentha G. Lack of evidence for ribavirin-induced bone loss. Hepatology 2002; 36: 255–257.
43. Hofmann WP, Kronenberger B, Bojunga J. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy. J Viral Hepat 2008; 15: 790–796.
44. Romero-Gómez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.
45. Ge D, Fellay J, Thompson AJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.